证券代码：301080 证券简称：百普赛斯 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 编号：2021-003 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：301080 证券简称：百普赛斯 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------- ...

证券代码：301080 证券简称：百普赛斯 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | |-------------------------|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

北京百普赛斯生物科技股份有限公司 2022 年第三季度报告 证券代码：301080 证券简称：百普赛斯 公告编号：2022-060 北京百普赛斯生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 北京百普赛斯生物科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|----------------------- ...

北京百普赛斯生物科技股份有限公司 2022 年半年度报告全文 北京百普赛斯生物科技股份有限公司 2022 年半年度报告 2022 年 8 月 1 北京百普赛斯生物科技股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人陈宜顶、主管会计工作负责人林涛及会计机构负责人(会计主 管人员)林涛声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告中涉及未来计划或规划等前瞻性陈述的，均不构成公司对 投资者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且 应当理解计划、预测与承诺之间的差异。 公司在本报告"第三节管理层讨论与分析"中"十、公司面临的风险和应对 措施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请投资者 关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 北京百普赛斯生物科技股份有限公司 2022 年半年度报告全文 目录 | ...

北京百普赛斯生物科技股份有限公司 2022 年第一季度报告全文 1 证券代码：301080 证券简称：百普赛斯 公告编号：2022-026 北京百普赛斯生物科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ ...

Financial Performance - The company reported a total revenue of RMB 800 million for the year 2021, representing a year-on-year increase of 25%[17]. - The net profit attributable to shareholders was RMB 150 million, an increase of 30% compared to the previous year[17]. - The company's operating revenue for 2021 was ¥384,987,712.08, representing a 56.30% increase compared to ¥246,318,612.85 in 2020[24]. - The net profit attributable to shareholders for 2021 was ¥174,214,119.79, a 50.34% increase from ¥115,882,563.52 in 2020[24]. - The net cash flow from operating activities for 2021 was ¥138,007,272.14, an increase of 43.02% compared to ¥96,496,412.20 in 2020[24]. - The total assets at the end of 2021 were ¥2,544,787,114.48, a significant increase of 1,039.04% from ¥223,414,218.19 at the end of 2020[24]. - The company reported a basic and diluted earnings per share of ¥2.7507 for 2021, which is a 42.42% increase from ¥1.9314 in 2020[24]. - In 2021, the company achieved total sales of approximately 2,500 products, including over 2,200 types of recombinant proteins[73]. - The company reported a significant increase in revenue, achieving a year-over-year growth of 25% in the last quarter[199]. Dividend and Cash Management - The company plans to distribute a cash dividend of RMB 15.00 per 10 shares, totaling RMB 120 million[5]. - The net increase in cash and cash equivalents was approximately ¥1.45 billion, reflecting a growth of 3,885.74% due to funds raised from the stock issuance on the Growth Enterprise Market[128]. - Cash and cash equivalents reached 2,007,380,846.75, accounting for 78.88% of total assets, a substantial increase from 41.57% at the beginning of the year[132]. Market Expansion and Growth Strategy - The company has set a revenue target of RMB 1 billion for 2022, indicating a growth expectation of 25%[17]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2023[17]. - The company plans to enhance its R&D capabilities by establishing new laboratories in Europe and expanding its global R&D footprint through acquisitions, focusing on protein preparation and clinical sample analysis technologies[163]. - Market expansion plans include entering three new international markets by the end of the year[200]. - The company is considering strategic acquisitions to enhance its market position, with a budget of $100 million allocated for potential deals[199]. Research and Development - Research and development expenses increased by 20% to RMB 100 million, focusing on innovative biotechnologies[17]. - The company has established R&D centers in China and the U.S., focusing on continuous technological and production process innovations[52]. - The company has developed multiple core technologies, including membrane protein expression and purification technology, to enhance its product offerings[52]. - The company aims to strengthen technology and product R&D, enhance production capacity, and expand into cell therapy and clinical sample analysis over the next 3-5 years[156]. - R&D investment reached approximately ¥59.55 million, accounting for 15.47% of operating revenue, an increase from 12.44% in the previous year[123]. Product Development and Offerings - New product launches are expected to contribute an additional RMB 200 million in revenue in 2022[17]. - The company has launched innovative products such as high-activity CD19 target proteins and neutralizing antibody screening kits, tailored to meet complex drug development needs[52]. - The company has developed over 2,200 types of recombinant proteins to support drug development, particularly in targeted and immune therapies for diseases like cancer and autoimmune disorders[63]. - The company has developed high-quality GMP-grade cytokines, such as IL-15 and IL-7, to support clinical research in immune cell therapies[65]. - The company has successfully developed various recombinant protein products targeting cutting-edge tumor immunotherapy, increasing product variety and quality[117]. Customer and Market Insights - User data showed a growth of 40% in active users, reaching 1.2 million by the end of 2021[17]. - Customer satisfaction ratings have improved to 90%, reflecting a 5% increase from the previous quarter[200]. - The sales revenue from products priced above 1 million accounted for 30.17% in 2020, which decreased to 2.30% in 2021[76]. Risk Management and Challenges - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[5]. - The company recognizes the risk of increased competition in the bioreagent and technical service industry, necessitating continuous improvement in technology and service capabilities to maintain market position[162]. - The company faces risks related to the rapid technological changes in the biopharmaceutical industry, emphasizing the need for ongoing R&D and talent acquisition to remain competitive[159]. - The company acknowledges the potential impact of U.S.-China trade tensions, with 36% of its overseas revenue coming from the U.S. market in 2021[161]. Corporate Governance and Management - The company is committed to maintaining high standards of corporate governance and transparency in its operations[196]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[180]. - The company has established an independent financial department with a complete and standardized accounting system, complying with relevant accounting regulations[181]. - The company has a strong management team with diverse backgrounds in biotechnology and finance, enhancing its operational capabilities[191]. Future Outlook - The company has a robust plan for future growth, including potential market expansions and new product launches[197]. - The company has provided a positive outlook for the next quarter, projecting a revenue growth of 20%[199]. - A new marketing strategy is being implemented, targeting a 30% increase in brand awareness within the next six months[200].

北京百普赛斯生物科技股份有限公司 2021 年第三季度报告 1 证券代码：301080 证券简称：百普赛斯 公告编号：2021-005 北京百普赛斯生物科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|----------------|-------------------------|----------------|----------- ...